McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.

McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 2027.

McKesson beats Q4 EPS estimates as oncology and specialty distribution growth offset revenue miss and lift segment margins.

McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript

Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

McKesson (MCK) came out with quarterly earnings of $11.69 per share, beating the Zacks Consensus Estimate of $11.56 per share. This compares to earnings of $10.12 per share a year ago.

McKesson forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates ​on Thursday, as the U.S. drug distributor ‌banks on strength in its oncology and specialty drug businesses.

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 7, at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and arch.